Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Two-Drug attack on advanced cervical cancer enters human testing

NCT ID NCT07080216

Summary

This study is testing a new combination of two drugs, ZG005 and gecacitinib, for women with advanced cervical cancer. The main goals are to find a safe dose and see if the treatment can shrink tumors. It will enroll about 120 participants to gather initial data on safety and effectiveness.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, 310022, China

    Contact

Conditions

Explore the condition pages connected to this study.